Clinical bottom line
Endobronchial valve (EBV) therapy is an established minimally invasive option for selected patients with severe emphysema, particularly those with heterogeneous disease and intact interlobar fissures. It can improve lung function, exercise capacity, and quality of life by inducing targeted lobar volume reduction. However, EBV therapy carries risks of valve-related complications such as pneumothorax and requires careful patient selection and post-procedure monitoring. Compared to lung volume reduction surgery (LVRS), EBV offers a less invasive alternative but may have higher costs and variable reimbursement. Current evidence supports EBV as a valuable adjunct or alternative to surgery in appropriate candidates, though long-term outcomes and cost-effectiveness remain areas for further study.
What the evidence shows
EBV therapy aims to reduce hyperinflation by occluding diseased emphysematous lobes, promoting atelectasis and improving respiratory mechanics. The IMPACT study (Hutchinson et al., 2017) demonstrated that EBV treatment in patients with severe homogeneous emphysema led to modest but clinically meaningful improvements in lung function and exercise tolerance. More recent data from Asian cohorts with up to 10 years of follow-up (Huh et al., 2024) confirm the durability of benefits and provide real-world insights into valve-related complications and management strategies.
Comparative analyses between EBV and LVRS in the United States reveal nuanced trade-offs. Hayanga et al. (2025) reported that while EBV therapy is associated with fewer perioperative risks and shorter hospital stays than LVRS, it incurs higher overall costs and lower reimbursement rates (Hayanga et al., 2026). This economic dimension may influence treatment decisions in different healthcare settings.
Emerging mechanistic studies also suggest cardiovascular benefits of EBV therapy. A prospective speckle-tracking echocardiography study (Li Zhuofan et al., 2026) indicated that EBV-induced lung volume reduction can favorably alter left ventricular mechanics, potentially improving cardiac function in severe emphysema patients.
Special populations, such as those with alpha-1 antitrypsin deficiency, have been studied with encouraging results. Hogarth et al. (2019) reported that EBV therapy is feasible and effective in this subgroup, expanding its applicability.
Valve-related complications remain a concern. Koster et al. (2020) provide a comprehensive overview of common issues such as pneumothorax, valve migration, and infections, emphasizing the importance of multidisciplinary management and patient education to mitigate risks.
Caveats and uncertainty
Despite promising outcomes, EBV therapy is not universally effective. Patient selection criteria, including the presence of intact interlobar fissures and absence of collateral ventilation, are critical but not always straightforward to assess. Variability in procedural expertise and post-procedural care can influence outcomes.
Long-term comparative effectiveness data versus LVRS are limited, especially regarding survival benefits and quality-adjusted life years. Economic analyses highlight higher costs for EBV therapy, but these may be offset by reduced morbidity and shorter recovery times; robust cost-effectiveness studies are needed.
Complication rates, particularly pneumothorax, can be significant and sometimes severe, requiring invasive interventions. The balance between benefits and risks must be carefully weighed on an individual basis.
Finally, most evidence derives from specialized centers and selected patient populations, which may limit generalizability to broader clinical practice.
How this may change practice
EBV therapy should be considered a key component of the therapeutic armamentarium for severe emphysema, especially for patients who are poor surgical candidates or prefer less invasive options. Pulmonologists and multidisciplinary teams must refine patient selection using advanced imaging and physiological assessments to optimize outcomes.
Centers offering EBV therapy need protocols for early detection and management of valve-related complications. Integration of cardiovascular assessment may further personalize therapy and identify patients who might derive additional cardiac benefits.
Economic considerations and reimbursement policies will influence adoption and accessibility. Clinicians should engage with payers and health systems to advocate for coverage based on emerging evidence.
Ongoing research and registries will clarify long-term outcomes and help define the role of EBV therapy relative to LVRS and medical management, guiding evidence-based, patient-centered care.